Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cannabis | 11 | 2022 | 439 | 4.250 |
Why?
|
Cannabinoids | 7 | 2021 | 166 | 3.040 |
Why?
|
Marijuana Abuse | 6 | 2020 | 403 | 1.900 |
Why?
|
Marijuana Smoking | 4 | 2020 | 253 | 1.630 |
Why?
|
Muscle Spasticity | 3 | 2017 | 154 | 1.550 |
Why?
|
Hallucinogens | 2 | 2022 | 180 | 1.320 |
Why?
|
Legislation, Drug | 4 | 2022 | 206 | 1.010 |
Why?
|
Opioid-Related Disorders | 7 | 2022 | 2065 | 0.940 |
Why?
|
Buprenorphine | 3 | 2022 | 640 | 0.830 |
Why?
|
N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2022 | 65 | 0.820 |
Why?
|
Cocaine-Related Disorders | 11 | 2008 | 460 | 0.650 |
Why?
|
Cannabidiol | 1 | 2020 | 106 | 0.630 |
Why?
|
Opiate Substitution Treatment | 2 | 2022 | 404 | 0.550 |
Why?
|
Psychiatry | 2 | 2021 | 1695 | 0.540 |
Why?
|
Naloxone | 2 | 2015 | 367 | 0.530 |
Why?
|
Government Regulation | 1 | 2019 | 522 | 0.490 |
Why?
|
Drug Industry | 4 | 2009 | 746 | 0.450 |
Why?
|
Burnout, Professional | 1 | 2021 | 694 | 0.440 |
Why?
|
Subclavian Steal Syndrome | 1 | 2012 | 23 | 0.420 |
Why?
|
Emergency Medicine | 1 | 2021 | 1207 | 0.420 |
Why?
|
Tobacco Use Disorder | 3 | 2013 | 688 | 0.400 |
Why?
|
Alcoholism | 3 | 2013 | 1906 | 0.390 |
Why?
|
DiGeorge Syndrome | 1 | 2012 | 177 | 0.370 |
Why?
|
Nicotine | 2 | 2013 | 681 | 0.370 |
Why?
|
Ductus Arteriosus, Patent | 1 | 2012 | 209 | 0.370 |
Why?
|
Neuralgia | 1 | 2015 | 570 | 0.330 |
Why?
|
Drug Approval | 1 | 2015 | 742 | 0.330 |
Why?
|
Phosphodiesterase 5 Inhibitors | 1 | 2009 | 101 | 0.310 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2009 | 215 | 0.310 |
Why?
|
Substance Abuse Detection | 3 | 2020 | 283 | 0.310 |
Why?
|
Psychotherapy | 5 | 2022 | 1643 | 0.310 |
Why?
|
Sumatriptan | 1 | 2007 | 65 | 0.300 |
Why?
|
Naproxen | 1 | 2007 | 99 | 0.300 |
Why?
|
Risk | 2 | 2017 | 9687 | 0.290 |
Why?
|
Sleep Apnea Syndromes | 1 | 2015 | 944 | 0.290 |
Why?
|
Prolactin | 5 | 2008 | 669 | 0.290 |
Why?
|
Amphetamine-Related Disorders | 1 | 2007 | 67 | 0.280 |
Why?
|
Marketing | 1 | 2008 | 212 | 0.280 |
Why?
|
Gift Giving | 1 | 2006 | 80 | 0.260 |
Why?
|
Anxiety Disorders | 1 | 2017 | 2690 | 0.260 |
Why?
|
Serotonin | 4 | 2008 | 1017 | 0.260 |
Why?
|
Biological Therapy | 1 | 2007 | 138 | 0.260 |
Why?
|
Combined Modality Therapy | 5 | 2022 | 8642 | 0.260 |
Why?
|
Marketing of Health Services | 1 | 2006 | 153 | 0.250 |
Why?
|
Biomedical Research | 2 | 2019 | 3309 | 0.250 |
Why?
|
Vomiting | 2 | 2020 | 636 | 0.250 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2022 | 4266 | 0.250 |
Why?
|
Substance-Related Disorders | 4 | 2019 | 4258 | 0.250 |
Why?
|
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2004 | 30 | 0.240 |
Why?
|
Humans | 60 | 2022 | 744343 | 0.240 |
Why?
|
Adolescent Behavior | 1 | 2013 | 1151 | 0.240 |
Why?
|
Vasoconstrictor Agents | 1 | 2007 | 642 | 0.240 |
Why?
|
Brain Diseases, Metabolic, Inborn | 1 | 2004 | 44 | 0.240 |
Why?
|
Nausea | 2 | 2019 | 673 | 0.230 |
Why?
|
Interview, Psychological | 1 | 2007 | 812 | 0.230 |
Why?
|
Health Surveys | 2 | 2015 | 4037 | 0.230 |
Why?
|
Conflict of Interest | 1 | 2008 | 544 | 0.230 |
Why?
|
Narcotic Antagonists | 4 | 2015 | 562 | 0.230 |
Why?
|
Physicians | 1 | 2021 | 4567 | 0.230 |
Why?
|
Pulmonary Artery | 1 | 2012 | 1912 | 0.230 |
Why?
|
Analgesics, Opioid | 6 | 2022 | 3674 | 0.230 |
Why?
|
Smoking Cessation | 2 | 2013 | 2071 | 0.220 |
Why?
|
Substance Abuse Treatment Centers | 2 | 2014 | 168 | 0.220 |
Why?
|
Serotonin Receptor Agonists | 4 | 2008 | 152 | 0.210 |
Why?
|
Cyclooxygenase 2 Inhibitors | 3 | 2009 | 320 | 0.210 |
Why?
|
Internship and Residency | 2 | 2021 | 5788 | 0.210 |
Why?
|
Membrane Transport Proteins | 3 | 2003 | 1028 | 0.210 |
Why?
|
Lactones | 3 | 2009 | 329 | 0.210 |
Why?
|
Sulfones | 3 | 2009 | 437 | 0.210 |
Why?
|
Epilepsy | 1 | 2017 | 3310 | 0.200 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 5 | 2008 | 322 | 0.200 |
Why?
|
Insulin-Secreting Cells | 1 | 2009 | 891 | 0.200 |
Why?
|
Policy | 2 | 2022 | 508 | 0.200 |
Why?
|
Vitamin B 12 | 1 | 2004 | 527 | 0.190 |
Why?
|
Ambulatory Care Facilities | 1 | 2007 | 933 | 0.190 |
Why?
|
Ethics, Medical | 1 | 2006 | 792 | 0.190 |
Why?
|
Paroxetine | 5 | 2008 | 182 | 0.190 |
Why?
|
Substance Withdrawal Syndrome | 3 | 2020 | 632 | 0.150 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 2282 | 0.150 |
Why?
|
Diabetic Neuropathies | 1 | 2021 | 400 | 0.150 |
Why?
|
Membrane Glycoproteins | 3 | 2003 | 3768 | 0.150 |
Why?
|
Defense Mechanisms | 1 | 2017 | 178 | 0.150 |
Why?
|
Pilot Projects | 4 | 2017 | 8324 | 0.140 |
Why?
|
Human Development | 1 | 2017 | 124 | 0.140 |
Why?
|
Canada | 2 | 2019 | 2065 | 0.140 |
Why?
|
Analgesics | 2 | 2021 | 1040 | 0.140 |
Why?
|
Piperazines | 4 | 2008 | 2488 | 0.140 |
Why?
|
Disease Progression | 1 | 2013 | 13284 | 0.140 |
Why?
|
Hypnotics and Sedatives | 1 | 2004 | 1162 | 0.130 |
Why?
|
Mental Health Services | 1 | 2007 | 1643 | 0.130 |
Why?
|
Behavior, Addictive | 2 | 2019 | 462 | 0.130 |
Why?
|
Carrier Proteins | 4 | 2003 | 5021 | 0.130 |
Why?
|
Nerve Tissue Proteins | 3 | 2003 | 4462 | 0.130 |
Why?
|
Migraine Disorders | 1 | 2007 | 1620 | 0.130 |
Why?
|
Family Relations | 1 | 2017 | 321 | 0.130 |
Why?
|
Cotinine | 2 | 2013 | 206 | 0.130 |
Why?
|
Social Adjustment | 1 | 2017 | 631 | 0.130 |
Why?
|
District of Columbia | 1 | 2014 | 157 | 0.120 |
Why?
|
Workplace | 1 | 2020 | 836 | 0.120 |
Why?
|
Blood Platelets | 5 | 2008 | 2508 | 0.120 |
Why?
|
Syndrome | 1 | 2020 | 3251 | 0.120 |
Why?
|
Alcoholics Anonymous | 1 | 2013 | 35 | 0.120 |
Why?
|
Wasting Syndrome | 1 | 2014 | 101 | 0.120 |
Why?
|
Adult | 23 | 2019 | 214055 | 0.110 |
Why?
|
Time | 1 | 2015 | 542 | 0.110 |
Why?
|
Clinical Trials as Topic | 2 | 2008 | 7913 | 0.110 |
Why?
|
Respiratory Tract Infections | 1 | 2020 | 961 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 9959 | 0.110 |
Why?
|
Antiemetics | 1 | 2014 | 177 | 0.110 |
Why?
|
Residential Treatment | 1 | 2013 | 111 | 0.110 |
Why?
|
Carbon Monoxide | 2 | 2013 | 531 | 0.110 |
Why?
|
Receptors, Serotonin | 2 | 2003 | 201 | 0.110 |
Why?
|
State Government | 1 | 2015 | 372 | 0.100 |
Why?
|
Norwood Procedures | 1 | 2014 | 182 | 0.100 |
Why?
|
Delirium | 1 | 2004 | 1609 | 0.100 |
Why?
|
Bipolar Disorder | 2 | 2012 | 5027 | 0.100 |
Why?
|
Pyridines | 1 | 2004 | 2825 | 0.100 |
Why?
|
Behavior Therapy | 1 | 2017 | 865 | 0.100 |
Why?
|
Multiple Sclerosis | 2 | 2017 | 3079 | 0.100 |
Why?
|
United States | 7 | 2021 | 69872 | 0.100 |
Why?
|
Subclavian Artery | 1 | 2012 | 130 | 0.100 |
Why?
|
Female | 25 | 2021 | 380194 | 0.100 |
Why?
|
Counseling | 2 | 2013 | 1523 | 0.100 |
Why?
|
Health Education | 1 | 2018 | 1056 | 0.100 |
Why?
|
Positive-Pressure Respiration | 1 | 2015 | 633 | 0.100 |
Why?
|
Administration, Cutaneous | 1 | 2013 | 711 | 0.100 |
Why?
|
Withholding Treatment | 1 | 2015 | 599 | 0.100 |
Why?
|
Narcotics | 1 | 2013 | 343 | 0.090 |
Why?
|
Polymorphism, Genetic | 3 | 2007 | 4328 | 0.090 |
Why?
|
Patient Education as Topic | 1 | 2020 | 2278 | 0.090 |
Why?
|
Mood Disorders | 1 | 2017 | 1106 | 0.090 |
Why?
|
Alcohol-Related Disorders | 1 | 2012 | 234 | 0.090 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2009 | 38 | 0.090 |
Why?
|
Neurodegenerative Diseases | 1 | 2019 | 1061 | 0.090 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2019 | 1432 | 0.090 |
Why?
|
United States Food and Drug Administration | 2 | 2015 | 1584 | 0.090 |
Why?
|
Impulsive Behavior | 2 | 2019 | 316 | 0.090 |
Why?
|
Male | 25 | 2017 | 350118 | 0.090 |
Why?
|
Psychotic Disorders | 1 | 2004 | 3046 | 0.080 |
Why?
|
Cycloserine | 1 | 2009 | 113 | 0.080 |
Why?
|
Ramipril | 1 | 2009 | 95 | 0.080 |
Why?
|
Diagnosis, Differential | 2 | 2015 | 12959 | 0.080 |
Why?
|
Seizures | 1 | 2020 | 2859 | 0.080 |
Why?
|
Deception | 1 | 2008 | 99 | 0.080 |
Why?
|
Age of Onset | 2 | 2013 | 3271 | 0.080 |
Why?
|
Sex Distribution | 1 | 2013 | 2297 | 0.080 |
Why?
|
Tablets | 1 | 2007 | 145 | 0.070 |
Why?
|
Carbolines | 1 | 2009 | 265 | 0.070 |
Why?
|
Adolescent | 5 | 2021 | 85781 | 0.070 |
Why?
|
Ethics Committees, Research | 1 | 2008 | 194 | 0.070 |
Why?
|
Psychotropic Drugs | 1 | 2012 | 894 | 0.070 |
Why?
|
Renin | 1 | 2009 | 642 | 0.070 |
Why?
|
Amlodipine | 1 | 2007 | 83 | 0.070 |
Why?
|
Adaptation, Psychological | 1 | 2017 | 2576 | 0.070 |
Why?
|
GABA Agonists | 1 | 2007 | 111 | 0.070 |
Why?
|
Pituitary Gland, Anterior | 1 | 2006 | 177 | 0.070 |
Why?
|
Cross-Over Studies | 2 | 2009 | 2029 | 0.070 |
Why?
|
Analysis of Variance | 2 | 2013 | 6365 | 0.070 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2009 | 469 | 0.070 |
Why?
|
Behavior | 2 | 2006 | 561 | 0.070 |
Why?
|
Ambulatory Care | 3 | 2013 | 2708 | 0.070 |
Why?
|
Disclosure | 2 | 2008 | 736 | 0.070 |
Why?
|
Aggression | 3 | 2006 | 753 | 0.070 |
Why?
|
Research Support as Topic | 2 | 2008 | 705 | 0.060 |
Why?
|
Nicotinic Agonists | 1 | 2007 | 271 | 0.060 |
Why?
|
Authorship | 1 | 2008 | 271 | 0.060 |
Why?
|
Sex Factors | 2 | 2013 | 10397 | 0.060 |
Why?
|
Drug Prescriptions | 1 | 2014 | 1637 | 0.060 |
Why?
|
Comorbidity | 2 | 2017 | 10388 | 0.060 |
Why?
|
Treatment Outcome | 9 | 2021 | 63114 | 0.060 |
Why?
|
Models, Statistical | 1 | 2019 | 5102 | 0.060 |
Why?
|
Medicaid | 1 | 2018 | 2736 | 0.060 |
Why?
|
Disease Management | 1 | 2015 | 2459 | 0.060 |
Why?
|
Risk Assessment | 4 | 2021 | 23338 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 2014 | 1956 | 0.060 |
Why?
|
Drive | 1 | 2003 | 35 | 0.060 |
Why?
|
Quality Indicators, Health Care | 1 | 2014 | 1831 | 0.060 |
Why?
|
Insurance Coverage | 1 | 2015 | 1901 | 0.060 |
Why?
|
Pain | 1 | 2019 | 4986 | 0.060 |
Why?
|
Feasibility Studies | 1 | 2013 | 5078 | 0.060 |
Why?
|
Public Health | 1 | 2016 | 2603 | 0.060 |
Why?
|
Patient Dropouts | 2 | 2002 | 421 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2013 | 2716 | 0.050 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 25043 | 0.050 |
Why?
|
Drug Combinations | 1 | 2007 | 1959 | 0.050 |
Why?
|
Cardiovascular System | 1 | 2009 | 832 | 0.050 |
Why?
|
Young Adult | 4 | 2017 | 56430 | 0.050 |
Why?
|
Mental Health | 1 | 2016 | 3019 | 0.050 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 1518 | 0.050 |
Why?
|
Age Factors | 2 | 2013 | 18370 | 0.050 |
Why?
|
Risk-Taking | 1 | 2007 | 986 | 0.050 |
Why?
|
Risk Factors | 3 | 2020 | 72290 | 0.050 |
Why?
|
Pandemics | 1 | 2021 | 8388 | 0.050 |
Why?
|
Valproic Acid | 1 | 2004 | 445 | 0.050 |
Why?
|
Mental Disorders | 1 | 2020 | 6600 | 0.050 |
Why?
|
Publishing | 1 | 2008 | 833 | 0.050 |
Why?
|
Double-Blind Method | 3 | 2009 | 12026 | 0.050 |
Why?
|
Gastrointestinal Diseases | 1 | 2008 | 1170 | 0.040 |
Why?
|
Massachusetts | 1 | 2013 | 8663 | 0.040 |
Why?
|
Hydrocodone | 1 | 1999 | 47 | 0.040 |
Why?
|
Cinnamates | 1 | 1999 | 60 | 0.040 |
Why?
|
Pregnancy | 1 | 2020 | 29144 | 0.040 |
Why?
|
Prospective Studies | 2 | 2017 | 53288 | 0.040 |
Why?
|
Middle Aged | 7 | 2017 | 213383 | 0.040 |
Why?
|
Receptors, Opioid, mu | 1 | 1999 | 182 | 0.040 |
Why?
|
Logistic Models | 1 | 2013 | 13408 | 0.040 |
Why?
|
Intracranial Pressure | 1 | 2000 | 326 | 0.040 |
Why?
|
Quality of Life | 2 | 2019 | 12804 | 0.040 |
Why?
|
Heart Defects, Congenital | 1 | 2014 | 4584 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2007 | 6489 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2007 | 10943 | 0.040 |
Why?
|
Seasons | 1 | 2003 | 1493 | 0.040 |
Why?
|
Blood Pressure | 2 | 2009 | 8554 | 0.030 |
Why?
|
Radioligand Assay | 2 | 2008 | 374 | 0.030 |
Why?
|
Astrocytoma | 1 | 2000 | 790 | 0.030 |
Why?
|
Urban Population | 1 | 2003 | 2021 | 0.030 |
Why?
|
Electroconvulsive Therapy | 1 | 2000 | 477 | 0.030 |
Why?
|
Patient Compliance | 2 | 2003 | 2684 | 0.030 |
Why?
|
Motivation | 2 | 2020 | 1971 | 0.030 |
Why?
|
Antidepressive Agents | 1 | 2007 | 2838 | 0.030 |
Why?
|
Outpatients | 1 | 2002 | 1486 | 0.030 |
Why?
|
Brain | 2 | 2019 | 26385 | 0.030 |
Why?
|
Heroin | 1 | 2014 | 117 | 0.030 |
Why?
|
Anticonvulsants | 1 | 2004 | 1916 | 0.030 |
Why?
|
Infant | 2 | 2014 | 35136 | 0.030 |
Why?
|
Injections, Intraventricular | 2 | 2007 | 230 | 0.030 |
Why?
|
Binding, Competitive | 2 | 2008 | 1157 | 0.030 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2004 | 1458 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 35421 | 0.030 |
Why?
|
Temporal Lobe | 1 | 2000 | 1670 | 0.030 |
Why?
|
Diagnosis, Dual (Psychiatry) | 1 | 2012 | 295 | 0.030 |
Why?
|
Reference Values | 3 | 2003 | 4982 | 0.020 |
Why?
|
North America | 1 | 2014 | 1249 | 0.020 |
Why?
|
Diffusion Tensor Imaging | 1 | 2019 | 2305 | 0.020 |
Why?
|
Cocaine | 2 | 2006 | 1007 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2009 | 11727 | 0.020 |
Why?
|
Severity of Illness Index | 4 | 2008 | 15540 | 0.020 |
Why?
|
Breath Tests | 1 | 2009 | 280 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 3508 | 0.020 |
Why?
|
Tritium | 1 | 2008 | 745 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2014 | 12245 | 0.020 |
Why?
|
Galvanic Skin Response | 1 | 2009 | 349 | 0.020 |
Why?
|
Radioimmunoassay | 1 | 2008 | 919 | 0.020 |
Why?
|
Aged | 4 | 2021 | 163280 | 0.020 |
Why?
|
Binding Sites | 2 | 2008 | 6114 | 0.020 |
Why?
|
Self Administration | 1 | 2007 | 385 | 0.020 |
Why?
|
Extinction, Psychological | 1 | 2009 | 376 | 0.020 |
Why?
|
Psychomotor Performance | 1 | 2014 | 1901 | 0.020 |
Why?
|
Review Literature as Topic | 1 | 2008 | 336 | 0.020 |
Why?
|
Polymerase Chain Reaction | 2 | 2006 | 6171 | 0.020 |
Why?
|
Prognosis | 2 | 2002 | 29063 | 0.020 |
Why?
|
Reoperation | 1 | 2014 | 4201 | 0.020 |
Why?
|
Hospitalization | 1 | 2004 | 10262 | 0.020 |
Why?
|
Palliative Care | 1 | 2019 | 3493 | 0.020 |
Why?
|
Cues | 1 | 2009 | 873 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7279 | 0.010 |
Why?
|
Receptors, Drug | 1 | 2003 | 160 | 0.010 |
Why?
|
Predictive Value of Tests | 2 | 2014 | 15076 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 6538 | 0.010 |
Why?
|
Self Report | 1 | 2014 | 3558 | 0.010 |
Why?
|
Philadelphia | 1 | 2003 | 266 | 0.010 |
Why?
|
Child Development | 1 | 2014 | 2223 | 0.010 |
Why?
|
Depressive Disorder, Major | 1 | 2000 | 4644 | 0.010 |
Why?
|
DNA Primers | 1 | 2006 | 2892 | 0.010 |
Why?
|
Odds Ratio | 1 | 2014 | 9849 | 0.010 |
Why?
|
Echocardiography | 1 | 2014 | 5102 | 0.010 |
Why?
|
Personality Assessment | 1 | 2003 | 647 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2017 | 13989 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2014 | 6993 | 0.010 |
Why?
|
Pennsylvania | 1 | 2002 | 613 | 0.010 |
Why?
|
Receptors, Dopamine | 1 | 2002 | 295 | 0.010 |
Why?
|
Heart Transplantation | 1 | 2014 | 3110 | 0.010 |
Why?
|
Length of Stay | 1 | 2014 | 6309 | 0.010 |
Why?
|
Time Factors | 2 | 2014 | 40075 | 0.010 |
Why?
|
Genotype | 2 | 2006 | 12951 | 0.010 |
Why?
|
Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 1999 | 36 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 12354 | 0.010 |
Why?
|
Gene Frequency | 1 | 2006 | 3588 | 0.010 |
Why?
|
Membranes | 1 | 1999 | 173 | 0.010 |
Why?
|
Databases, Factual | 1 | 2014 | 7729 | 0.010 |
Why?
|
Quality Improvement | 1 | 2014 | 3749 | 0.010 |
Why?
|
Enkephalins | 1 | 1999 | 154 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2000 | 8863 | 0.010 |
Why?
|
Personality Inventory | 1 | 2002 | 1030 | 0.010 |
Why?
|
Dominance, Cerebral | 1 | 2000 | 635 | 0.010 |
Why?
|
Mice, Inbred ICR | 1 | 1999 | 352 | 0.010 |
Why?
|
Regression Analysis | 1 | 2008 | 6459 | 0.010 |
Why?
|
Central Nervous System Stimulants | 1 | 2006 | 1148 | 0.010 |
Why?
|
Neostriatum | 1 | 1999 | 250 | 0.010 |
Why?
|
Neurologic Examination | 1 | 2000 | 930 | 0.010 |
Why?
|
Animals | 2 | 2007 | 168757 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2014 | 19905 | 0.010 |
Why?
|
Heart Rate | 1 | 2007 | 4091 | 0.010 |
Why?
|
Brain Edema | 1 | 2000 | 617 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2006 | 5867 | 0.010 |
Why?
|
Morphine | 1 | 1999 | 657 | 0.010 |
Why?
|
Cattle | 1 | 1999 | 3922 | 0.010 |
Why?
|
Reaction Time | 1 | 1999 | 2097 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2014 | 15295 | 0.010 |
Why?
|
Ligands | 1 | 1999 | 3282 | 0.010 |
Why?
|
Incidence | 1 | 2009 | 20947 | 0.010 |
Why?
|
Pain Measurement | 1 | 1999 | 3420 | 0.010 |
Why?
|
Patient Care Team | 1 | 2000 | 2531 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2006 | 21746 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2004 | 39050 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2000 | 20129 | 0.000 |
Why?
|
Mice | 1 | 1999 | 81183 | 0.000 |
Why?
|